SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. The company announced positive results in a Phase II trial to treat agitation associated with Alzheimer's Disease.
‍

As with most small cap announcements for the treatment of AD, the stock rose +44% on the news quickly, sold off quickly, then rose +27%.

Patient investors were rewarded on this trade.
‍

If successful in phase III and commercial development, the drug could generate tens of millions of dollars. The company is currently valued at $3.5M.
‍

The trial focused on their proprietary drug, SCI-110, and its effects on Alzheimer's patients. The results showed that SCI-110 was both safe and effective in reducing agitation in elderly patients with Alzheimer's.
‍

LevelFields users were alerted to the breakthrough within the Alzheimer's Breakthrough scenario on Wednesday morning.

‍

LevelFields AI analyzes millions of events from documents, news items and financial filings to find events that move stocks. You can use it to find profitable trades, no matter how the market moves. Click the image below to signup.
‍

‍

‍